Member Info for Fredd1eboy

....form of ludite charity spending donation monies at a loss in order to scupper us. Its being going on for years. Whowever it is cannot be making money just attacking Reneuron. I've held this conspiracy theory for years. Second thoughts a wealthy competitor. I know you will probably think me mad and you could be right, but any other more down to earth suggestions would be appreciated.

....form of ludite charity spending donation monies at a loss in order to scupper us. Its being going on for years. Whowever it is cannot be making money just attacking Reneuron. I've held this conspiracy theory for years. Second thoughts a wealthy competitor. I know you will probably think me mad and you could be right, but any other more down to earth suggestions would be appreciated.

...investment from the Welsh HM Government Office, Neil Woodford, Prof Sir Chris Evans along with many small investors supporting us. So my congratulations to all involved in supporting our excellent Reneuron research team. I hope Reneuron will seriously consider listing on other markets as the AIM market appears to be too easily manipulated by a very sad destructive investment culture.

If the market doesn't recognize the importance of this, then Olav and his team cannot be blamed. It just confirms the city is only interested in making a short term buck at the expense of those companies trying to make a difference for the benefit of humanity. One day the penny will drop. Probably mainland Europe or the US will carry us forward. Personally I have lost confidence in the uk's Institutional blinkered approach to investing.

.... We take this feedback as an endorsement of our proposed approach to this important clinical trial and further recognition of the very large unmet medical need represented by patients left with lasting disabilities following an ischaemic stroke."

I also particularly like the message.. Breakthrough Therapy designation, including increased interactions with the FDA during development and eligibility for priority review and accelerated marketing approval.

For info.... Fellow bed-sitters at the heart-break-hotel. Whilst a lot of us have been here since 2009 and before, I know there is a substantial sub-set of us who are in here with big money, I mean big... £100k plus mulah. Either way, it is less than a dog's breakfast we're being served over the years. So I would like to share an official response to a very pointed and direct email I sent to the CEO & CFO recently regarding the building-jumping sp in the 1p!!! I can only hope this keeps us on the ledge... Thank you for your email and for your support of ReNeuron. The company very much believes that its current share price undervalues the company but, as you are aware, it is the market, through investors’ buying and selling shares, that dictates the share price and not the company itself. That said, ReNeuron has wide-ranging investor relations activities to promote the company and to develop the market for its shares. These activities embrace both institutional and private investors and include institutional investor roadshows at least twice a year, analyst meetings at least twice a year, presentations at banking conferences in the UK and US, presentations at private investor conferences and regular media outreach. ReNeuron webcasts its analyst meetings so that private investors can access the same information as research analysts and it provides considerable information on its website for both institutional and private investors. As you aware, ReNeuron has made major progress in advancing its clinical work and earlier stage technology and, as this progress continues, it is reasonable to expect that it will be reflected in the company share price. Please let me know if I can be of further assistance. Kind regards,

We are promised key updates H1 2017, which I read as this month. Best wishes freddie

Its a buy for me winklebelly. Just wish I had more cash. News soon and hopefully good news. Best wishes. Freddie

Has anyone recently looked at the sp. 1.9p to sell 2p buy.........I despair..........the volume of trading is low and no one appears interested in buying.......why!!!!!

Title should read anyone notice

Snuck in much later.... 16:00:00. 2.05p....973,121. £19.95k

...I have to admit to knowing very little about recent events which may have caused the crash in sp. Anyone any views they can share with me while I consider dipping my toes in or not? Best wishes. Freddie

I agree with you sheer. Our major investors are in at 5p plus. An agreed takeover bid would commence at 6p plus. My guess is low sp due to low trading. Olav Hellobo has to improve on his PR skills fully capitalise on any (hopefully a lot) good news to come. Starting point FDA REN001 phase 3 trials commencement approval....I just hope there are no obstacles. |The rest then follow Rens 003/009, facility licensing approvals....Japan, exosome's..the list goes on. He has to do a lot of good for me to forgive him letting the sp collapse to 2p....

Thanks dibs...keep in me on the straight and narrow....have a good weekend. Freddie

Good thought gige and long overdue. Best wishes. Freddie

...is there anything to stop Reneuron buying back shares at just over 2p funded with some of the cash it has in the bank or do they have to declare intentions beforehand? The reason for asking....Plenty of buying going on now for days at around 2p. If they are.confident of goods news to follow and with interest rates so low wouldn't it be a good idea? Go on someone tell me you cannot do it?

Andrew Marr !

esents positive exosome data at major conference Thu, 18th May 2017 07:00 RNS Number : 4700F ReNeuron Group plc 18 May 2017 AIM: RENE 18 May 2017 ReNeuron Group plc ReNeuron presents positive pre-clinical data with its ExoPr0 exosome therapy candidate at major scientific conference Data show that ExoPr0 can cross the blood brain barrier and can potentially target multiple diseases via local or systemic administration ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it will be presenting new positive pre-clinical data relating to its ExoPr0 CTX cell-derived exosome therapy candidate at a leading scientific conference. In this poster presentation, ReNeuron researchers will describe studies undertaken to investigate the in vivo biodistribution of ExoPr0, using the most common and disease applicable routes of administration to deliver the exosomes. The studies showed that ExoPr0 can be targeted to specific organs and tissues by either local or systemic administration. The uptake of ExoPr0 by particular cell types in target organs suggests that there also may be some specificity in uptake at the cellular level. ReNeuron has identified the potential of ExoPr0 as both a novel therapeutic candidate and as a drug delivery vehicle, based on earlier research to demonstrate the ability of ExoPr0 to modulate fibroblasts, immune cells and cancer cell lines in vitro. This earlier work, together with these new findings showing that ExoPr0 can be targeted to specific tissues and organs and, most importantly, can penetrate the blood brain barrier, suggest that there is significant potential to develop ExoPr0 for the treatment of multiple diseases. The above findings are being presented today at the International Society for Extracellular Vesicles (ISEV) 2017 Annual Meeting in Toronto, Canada. Further information about this conference may be found at www.isev.org/page/ISEV2017 Dr Randolph Corteling, Head of Research at ReNeuron, said: "We are very encouraged by the findings being presented at the ISEV 2017 conference relating to our ExoPr0 exosome therapy candidate. The ability to target ExoPr0 to specific tissues and organs, including the brain, via clinically relevant routes of administration is highly significant. This, together with other recent positive data we have presented relating to the characterisation and scale-up potential of our exosome therapy candidates, clearly demonstrate the potential of this novel therapeutic platform to target multiple diseases."

....With all that cash in the bank and progress on research.....shame on you Olav!